The cost of a mis-hire in medical devices.

There is a number most medical device finance teams have never calculated, even though they have lived through the event it describes.

The number is not what the recruiter charged. It is not the salary paid for sixteen months before the conversation about "not being the right fit" finally took place. It is the sum of everything the company cannot see on a spreadsheet: the distributor relationships that cooled while the wrong person held the territory, the KOL who stopped returning calls after the third unsupported promise, the CPT code application that sat at draft stage for a quarter because nobody in the building owned it properly, and the six-month gap between the exit conversation and the moment a replacement was ready to generate revenue.

The recruiter's fee is usually the smallest number in that list. Not even close.

What the standard models miss

Geoff Smart and Randy Street, in their research on executive hiring, estimated a 15x base salary cost for a VP-level mis-hire. For a VP Sales on a £250,000 base, that's £3.75 million. The number sounds extreme until you build it component by component. This piece does exactly that for medical devices specifically, because the sector has cost categories that don't exist anywhere else.

The four cost categories

The first is the direct and visible cost: the search fee paid, the salary and package paid during tenure, onboarding time, management attention during induction, and the cost of the replacement search. A retained search at VP level typically runs at 25–33% of first-year compensation. That fee, combined with salary payments for 12–18 months and the cost of a second search, typically produces a direct cost figure of between £300,000 and £500,000 before anything else is counted.

The second category is revenue delay. A medical device VP Sales typically takes 6–9 months to reach full productivity from a standing start. When the wrong hire exits at month fourteen or sixteen, the replacement has to start that ramp from scratch.

The company doesn't lose one ramp period. It loses two.

At realistic deal values for a medical device in a secondary care environment, six months of reduced productivity in a VP Sales role costs between £400,000 and £800,000 in deferred revenue, depending on the product and territory. Conservative.

The third category is relationship damage. It doesn't appear anywhere on a P&L.

A distributor network built over two years on personal credibility resets materially when the face behind those relationships changes. A KOL who agreed to participate in a clinical advisory board because of their relationship with the individual, not the company, doesn't necessarily extend that commitment to the replacement. Change the account lead on a VAC submission mid-process and you've lost three months of groundwork. None of this is recoverable on day one. The replacement needs time to rebuild, and during that period, the competitor whose commercial leader is still in post isn't standing still.

The fourth category has no equivalent outside medical devices.

The window you can't get back

In a post-clearance, pre-established-reimbursement company, the commercial leadership hire doesn't just determine revenue for the coming year. It determines whether the company uses its commercial window or loses it.

The period between FDA clearance and established Category I CPT code coverage averages 3–7 years. Every sale during that stretch requires active reimbursement management: the company is operating on a temporary or miscellaneous code, which means nothing is automatic. The KOL relationships being built now generate the real-world evidence that supports the permanent code application. What payers hear in this window determines MAC coverage decisions later. The physician education programme running in parallel shapes adoption patterns that persist long after the window closes.

A VP Sales hired into this environment who carries the behavioural profile of a scaling operator rather than a market-builder doesn't simply underperform.

They consume the window without filling it.

By the time the company recognises the structural problem, 18 months of the most commercially sensitive period in the device's lifecycle have been spent on a hire that was never going to work. That's what 15x base salary is measuring: not just what was lost, but what was never built.

Why it keeps happening

A mis-hire is rarely a failure of capability. The candidate who lasted fourteen months usually had an impressive CV, and they'd hit numbers before. They interviewed well, which is a low bar.

The error, in most cases, is structural: the company hired for the role it understood rather than the stage it was actually in.

So why does it keep happening?

The pattern that appears most consistently across placements in early-stage medical devices is what I'd describe as the scaling operator in a pioneer role. A candidate who built a high-performing sales team from 30 to 100 reps at an established device company, who managed £80 million of revenue against a mature reimbursement environment, and who was brought in to build a market from scratch that did not yet have physician awareness, payer coverage, or a KOL community. Real skills. Wrong context. The behavioural profile that made the scaling operator successful (high sociability, relationship management, systematic territory coverage) is precisely the profile that struggles in a greenfield launch environment where the first twelve months require a different disposition entirely.

Bradford Smart's research in Topgrading puts 300 hours of management time as the cost of a single senior mis-hire across recruitment, coaching, performance management, exit management, and replacement. Not the worst of it. The worst is what wasn't built while the right person wasn't in the seat.

What the arithmetic says about the search fee

A retained VP-level search costs 25–33% of first-year compensation. On a £250,000 package: between £62,500 and £82,500.

The same role, hired wrongly through a process that prioritised speed and CV presentation over stage fit and behavioural alignment, costs somewhere between £700,000 and £1.2 million by the conservative estimates in this piece. That figure excludes the commercial window cost, which for a post-clearance device company at the critical reimbursement-building stage cannot be captured in a single number: the compound effect of 18 lost months doesn't stop accumulating when the replacement arrives.

The question medical device executives should be asking at budget approval stage is not whether they can justify the search fee.

It's whether they can absorb the cost of the alternative.